display
Mainz (dpa) - According to the manufacturer, the vaccine from Biontech / Pfizer also reliably protects young people from Covid 19 disease.
That comes from the results of a study with 2260 young people between 12 and 15 years in the USA, which Biontech and Pfizer published on Wednesday.
The participants would have tolerated the vaccine well.
"The side effects were comparable to those in 16 to 25 year olds," it said.
However, the results have not yet been assessed by experts and published in a specialist journal.
According to their own statements, Biontech and Pfizer plan to submit the data to the EU approval authority EMA and its US counterpart FDA in the coming weeks.
"We hope that we can start vaccinating this age group before the start of the next school year," said Pfizer boss Albert Bourla, according to the announcement.
So far, there has only been conditional approval in the EU for people aged 16 and over.
In the pivotal phase 3 study, half of the participants received the mRNA vaccine, the other half a placebo.
Among the unvaccinated adolescents, 18 later contracted corona, none of the vaccinated.
Based on this, the manufacturers give the effectiveness in adolescents with 100 percent.
In addition, studies have shown that vaccinated adolescents develop a very clear antibody response.
display
A few days ago, Biontech and Pfizer announced that they had also started studies in younger children (from six months up to and including 11 years of age).
© dpa-infocom, dpa: 210331-99-41246 / 2